Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matisyahu Shulman

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
Substance Use & Misuse|August 17, 2022
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable NaltrexoneMiranda G Greiner, Matisyahu Shulman, Jennifer Scodes, et al.
Contemporary Clinical Trials|April 24, 2024
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trialMatisyahu Shulman, Scott Provost, Kaitlyn Ohrtman, et al.
Contemporary Clinical Trials|January 22, 2025
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)Matisyahu Shulman, Sarah Meyers-Ohki, Patricia Novo, et al.
Drug and Alcohol Dependence Reports|January 16, 2023
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorderKathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, et al.
JAMA Network Open|May 8, 2024
Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical TrialMatisyahu Shulman, Miranda G Greiner, Hiwot M Tafessu, et al.
Contemporary Clinical Trials|March 17, 2023
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation studyMiranda G Greiner, Matisyahu Shulman, Onumara Opara, et al.
Trials|January 29, 2021
Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus studyNiranjan S Karnik, Cynthia I Campbell, Megan E Curtis, et al.
Addiction (Abingdon, England)|March 16, 2022
The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus studyNiranjan S Karnik, John Marsden, Connor McCluskey, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
Substance Use & Misuse|August 17, 2022
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable NaltrexoneMiranda G Greiner, Matisyahu Shulman, Jennifer Scodes, et al.
Contemporary Clinical Trials|April 24, 2024
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trialMatisyahu Shulman, Scott Provost, Kaitlyn Ohrtman, et al.
Contemporary Clinical Trials|January 22, 2025
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)Matisyahu Shulman, Sarah Meyers-Ohki, Patricia Novo, et al.
Drug and Alcohol Dependence Reports|January 16, 2023
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorderKathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, et al.
JAMA Network Open|May 8, 2024
Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical TrialMatisyahu Shulman, Miranda G Greiner, Hiwot M Tafessu, et al.
Contemporary Clinical Trials|March 17, 2023
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation studyMiranda G Greiner, Matisyahu Shulman, Onumara Opara, et al.
Trials|January 29, 2021
Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus studyNiranjan S Karnik, Cynthia I Campbell, Megan E Curtis, et al.
Addiction (Abingdon, England)|March 16, 2022
The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus studyNiranjan S Karnik, John Marsden, Connor McCluskey, et al.
Pageof 4